Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment

Study 118 Team

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


In HIV-1-infected treatment-naive patients with mild-to-moderate renal impairment [creatinine clearance (CrCl): 50-89 mL/min], elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB, n 33) achieved high rates of virologic success (78.8%; 95% confidence interval: 61.1% to 91.0%) and was well tolerated through week 48. Four patients discontinued study drug due to an adverse event and none due to proximal renal tubulopathy. As expected, decreases in CrCl were noted as early as week 2, after which they stabilized. The renal safety profile of STB in patients from this study is consistent with the long-term experience in a large number of patients with CrCl ≥70 mL/min.

Original languageEnglish
Pages (from-to)310-313
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Issue number3
StatePublished - 1 Mar 2015


  • HIV
  • elvitegravir/cobicistat/emtricitabine/tenofovir DF
  • renal impairment
  • renal safety


Dive into the research topics of 'Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment'. Together they form a unique fingerprint.

Cite this